Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

Hematopoietic stem cell transplantation (HSCT) is the only curative therapy for patients with myelodysplastic syndrome (MDS). However, the morbidity and mortality associated with conventional HSCT have traditionally prevented many patients from undergoing such treatment. Recent advances, including b...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yi-Bin, Ballen, Karen K
Formato: Texto
Lenguaje:English
Publicado: Medicine Reports Ltd 2009
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920696/
https://www.ncbi.nlm.nih.gov/pubmed/20948771
http://dx.doi.org/10.3410/M1-11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920696/
https://www.ncbi.nlm.nih.gov/pubmed/20948771
http://dx.doi.org/10.3410/M1-11

Ejemplares similares